Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy

JAMA Dermatology

Volumn 150, Issue 11, 2014, Pages 1209-1212

  Chen, Frank W ^a   Tseng, Diane ^b   Reddy, Sunil ^c   Daud, Adil I ^d   Swetter, Susan M ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; COBIMETINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; VEMURAFENIB; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; B RAF KINASE; BRAF PROTEIN, HUMAN; GDC-0973; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PIPERIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; ENZYME INHIBITION; ERUPTIVE MELANOCYTIC NEVUS; ERYTHEMA NODOSUM; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; MELANOCYTIC NEVUS; MELANOMA; MONOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG INTERACTION; PATHOLOGY; PIGMENTED NEVUS; SKIN NEOPLASMS; YOUNG ADULT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZETIDINES; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLES; MAP KINASE KINASE 1; MELANOMA; NEVUS, PIGMENTED; PIPERIDINES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84910115731     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.838     Document Type: Article

References (15)

1. Jiménez-Gallo D, Albarrán-Planelles C, Linares-BarriosM, Martínez-Rodríguez A, Báez-Perea JM. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol. 2013;149(5):624-626.
2. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6): 1691-1697.
3. Chu EY,Wanat KA,Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265-1272.
4. Dalle S, Poulalhon N, Debarbieux S, et al. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol. 2013;149(4):488-490.
5. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18): 1694-1703.
7. Cohen PR, Bedikian AY, Kim KB. Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol. 2013;6(5):27-37.
8. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51-65.
9. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131-1155.
10. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-215.
11. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15(3):249-254.
12. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436(7051): 720-724.
13. Terushkin V, Scope A, Halpern AC, Marghoob AA. Pathways to involution of nevi: insights from dermoscopic follow-up. Arch Dermatol. 2010;146 (4):459-460.
14. Martín JM, RubioM, Bella R, Jordá E, Monteagudo C. Complete regression of melanocytic nevi: correlation between clinical, dermoscopic, and histopathologic findings in 13 patients [in Spanish]. Actas Dermosifiliogr. 2012;103 (5):401-410.
15. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-1231.